Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Snail1 expression in colorectal cancer and its correlation with clinical and pathological parameters

Authors: Feride Kroepil, Georg Fluegen, Daniel Vallböhmer, Stephan E Baldus, Levent Dizdar, Andreas M Raffel, Dieter Hafner, Nikolas H Stoecklein, Wolfram T Knoefel

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Snail1 is a transcription regulator of E-cadherin. The loss of E-cadherin seems to be a crucial step in the process of Epithelial-mesenchymal transition (EMT). EMT initiates invasion and proliferation in many tumours. Overexpression of Snail1 is known to be associated with poor outcome in several solid tumours. The aim of this study was to analyse its expression profile and prognostic significance in colorectal cancer.

Methods

Tissue microarrays (TMA) containing paraffin-embedded primary colorectal cancer (CRC) tissue samples from 251 patients were used in this study. The expression of Snail1 and E-cadherin was assessed by immunohistochemistry in different tumour compartments, corresponding lymph node metastases and normal colonic mucosa. Intensity of staining was classified according to the Remmele score (standardized scoring system) as well as the semiquantitative score established by Blechschmidt et al.

Results

Snail1 expression was observed in 76% of the CRC. Loss of E-cadherin was noted in 87% of the CRC. Snail1 positive tumours were significantly correlated with Snail1 positive lymph node metastases (p=0.03). There was no significant correlation between loss of E-cadherin and Snail1 expression, or between N-stage or grading and Snail1 expression. Kaplan-Meier survival analysis identified no prognostic impact of Snail1 expression on overall survival.

Conclusion

Snail1 expression was detectable in most of the CRC but showed no significant association with E-cadherin loss, clinical pathological characteristics or overall survival. The observed loss of E-cadherin could be explained by effects of other important EMT pathways, such as the Wnt-signalling cascade.
Appendix
Available only for authorised users
Literature
1.
Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J: Garcia De Herreros A: The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2000, 2 (2): 84-89. 10.1038/35000034.CrossRefPubMed
2.
Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA: The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2000, 2 (2): 76-83. 10.1038/35000025.CrossRefPubMed
3.
van Roy F, Berx G: The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci. 2008, 65 (23): 3756-3788. 10.1007/s00018-008-8281-1.CrossRefPubMed
4.
Polyak K, Weinberg RA: Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009, 9 (4): 265-273. 10.1038/nrc2620.CrossRefPubMed
5.
Roussos ET, Keckesova Z, Haley JD, Epstein DM, Weinberg RA, Condeelis JS: AACR special conference on epithelial-mesenchymal transition and cancer progression and treatment. Cancer Res. 2010, 70 (19): 7360-7364. 10.1158/0008-5472.CAN-10-1208.CrossRefPubMed
6.
Thiery JP, Acloque H, Huang RY, Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 2009, 139 (5): 871-890. 10.1016/j.cell.2009.11.007.CrossRefPubMed
7.
Bezdekova M, Brychtova S, Sedlakova E, Langova K, Brychta T, Belej K: Analysis of snail-1, e-cadherin and claudin-1 expression in colorectal adenomas and carcinomas. Int J Mol Sci. 2012, 13 (2): 1632-1643. 10.3390/ijms13021632.CrossRefPubMedPubMedCentral
8.
Solanas G, Porta-de-la-Riva M, Agusti C, Casagolda D, Sanchez-Aguilera F, Larriba MJ, Pons F, Peiro S, Escriva M, Munoz A: E-cadherin controls beta-catenin and NF-kappaB transcriptional activity in mesenchymal gene expression. J Cell Sci. 2008, 121 (Pt 13): 2224-2234.CrossRefPubMed
9.
Stemmer V, de Craene B, Berx G, Behrens J: Snail promotes Wnt target gene expression and interacts with beta-catenin. Oncogene. 2008, 27 (37): 5075-5080. 10.1038/onc.2008.140.CrossRefPubMed
10.
Larriba MJ, Valle N, Palmer HG, Ordonez-Moran P, Alvarez-Diaz S, Becker KF, Gamallo C, de Herreros AG, Gonzalez-Sancho JM, Munoz A: The inhibition of Wnt/beta-catenin signalling by 1alpha,25-dihydroxyvitamin D3 is abrogated by Snail1 in human colon cancer cells. Endocr Relat Cancer. 2007, 14 (1): 141-151. 10.1677/ERC-06-0028.CrossRefPubMed
11.
Poser I, Dominguez D, de Herreros AG, Varnai A, Buettner R, Bosserhoff AK: Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repressor Snail. J Biol Chem. 2001, 276 (27): 24661-24666. 10.1074/jbc.M011224200.CrossRefPubMed
12.
Yokoyama K, Kamata N, Hayashi E, Hoteiya T, Ueda N, Fujimoto R, Nagayama M: Reverse correlation of E-cadherin and snail expression in oral squamous cell carcinoma cells in vitro. Oral Oncol. 2001, 37 (1): 65-71. 10.1016/S1368-8375(00)00059-2.CrossRefPubMed
13.
Blanco MJ, Moreno-Bueno G, Sarrio D, Locascio A, Cano A, Palacios J, Nieto MA: Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene. 2002, 21 (20): 3241-3246. 10.1038/sj.onc.1205416.CrossRefPubMed
14.
Jiao W, Miyazaki K, Kitajima Y: Inverse correlation between E-cadherin and Snail expression in hepatocellular carcinoma cell lines in vitro and in vivo. Br J Cancer. 2002, 86 (1): 98-101. 10.1038/sj.bjc.6600017.CrossRefPubMedPubMedCentral
15.
Katoh M: Epithelial-mesenchymal transition in gastric cancer (Review). Int J Oncol. 2005, 27 (6): 1677-1683.PubMed
16.
Franci C, Gallen M, Alameda F, Baro T, Iglesias M, Virtanen I: Garcia de Herreros A: Snail1 protein in the stroma as a new putative prognosis marker for colon tumours. PLoS One. 2009, 4 (5): e5595-10.1371/journal.pone.0005595.CrossRefPubMedPubMedCentral
17.
Peinado H, Olmeda D, Cano A: Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer. 2007, 7 (6): 415-428.CrossRefPubMed
18.
Olmeda D, Jorda M, Peinado H, Fabra A, Cano A: Snail silencing effectively suppresses tumour growth and invasiveness. Oncogene. 2007, 26 (13): 1862-1874. 10.1038/sj.onc.1209997.CrossRefPubMed
19.
Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell. 2011, 144 (5): 646-674. 10.1016/j.cell.2011.02.013.CrossRefPubMed
20.
Loboda A, Nebozhyn MV, Watters JW, Buser CA, Shaw PM, Huang PS, Van't Veer L, Tollenaar RA, Jackson DB, Agrawal D: EMT is the dominant program in human colon cancer. BMC Med Genomics. 2011, 4: 9-10.1186/1755-8794-4-9.CrossRefPubMedPubMedCentral
21.
Kroepil F, Fluegen G, Totikov Z, Baldus SE, Vay C, Schauer M, Topp SA, Esch JS, Knoefel WT, Stoecklein NH: Down-regulation of CDH1 is associated with expression of SNAI1 in colorectal adenomas. PLoS One. 2012, 7 (9): e46665-10.1371/journal.pone.0046665.CrossRefPubMedPubMedCentral
22.
Roy HK, Smyrk TC, Koetsier J, Victor TA, Wali RK: The transcriptional repressor SNAIL is overexpressed in human colon cancer. Dig Dis Sci. 2005, 50 (1): 42-46. 10.1007/s10620-005-1275-z.CrossRefPubMed
23.
Yusra S: S, Yokozaki H: Biological significance of tumor budding at the invasive front of human colorectal carcinoma cells. Int J Oncol. 2012, 41 (1): 201-210.PubMed
24.
Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998, 4 (7): 844-847. 10.1038/nm0798-844.CrossRefPubMed
25.
Remmele W, Hildebrand U, Hienz HA, Klein PJ, Vierbuchen M, Behnken LJ, Heicke B, Scheidt E: Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer. Virchows Arch A Pathol Anat Histopathol. 1986, 409 (2): 127-147. 10.1007/BF00708323.CrossRefPubMed
26.
Blechschmidt K, Sassen S, Schmalfeldt B, Schuster T, Hofler H, Becker KF: The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. Br J Cancer. 2008, 98 (2): 489-495. 10.1038/sj.bjc.6604115.CrossRefPubMed
27.
Dominguez D, Montserrat-Sentis B, Virgos-Soler A, Guaita S, Grueso J, Porta M, Puig I, Baulida J, Franci C: Garcia de Herreros A: Phosphorylation regulates the subcellular location and activity of the snail transcriptional repressor. Mol Cell Biol. 2003, 23 (14): 5078-5089. 10.1128/MCB.23.14.5078-5089.2003.CrossRefPubMedPubMedCentral
28.
Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, Hung MC: Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol. 2004, 6 (10): 931-940. 10.1038/ncb1173.CrossRefPubMed
29.
Zhu Y, Nilsson M, Sundfeldt K: Phenotypic plasticity of the ovarian surface epithelium: TGF-beta 1 induction of epithelial to mesenchymal transition (EMT) in vitro. Endocrinology. 2010, 151 (11): 5497-5505. 10.1210/en.2010-0486.CrossRefPubMed
30.
Samuel S, Walsh R, Webb J, Robins A, Potten C, Mahida YR: Characterization of putative stem cells in isolated human colonic crypt epithelial cells and their interactions with myofibroblasts. Am J Physiol Cell Physiol. 2009, 296 (2): C296-305.CrossRefPubMed
31.
Southall TD, Brand AH: Neural stem cell transcriptional networks highlight genes essential for nervous system development. EMBO J. 2009, 28 (24): 3799-3807. 10.1038/emboj.2009.309.CrossRefPubMedPubMedCentral
32.
33.
Chui MH: Insights into cancer metastasis from a clinicopathologic perspective: Epithelial mesenchymal transition is not a necessary step. Int J Cancer. 2012, 132 (7): 1487-1795.CrossRefPubMed
34.
Zhu LF, Hu Y, Yang CC, Xu XH, Ning TY, Wang ZL, Ye JH, Liu LK: Snail overexpression induces an epithelial to mesenchymal transition and cancer stem cell-like properties in SCC9 cells. Lab Invest. 2012, 92 (5): 744-752. 10.1038/labinvest.2012.8.CrossRefPubMed
35.
Neal CL, Henderson V, Smith BN, McKeithen D, Graham T, Vo BT, Odero-Marah VA: Snail transcription factor negatively regulates maspin tumor suppressor in human prostate cancer cells. BMC Cancer. 2012, 12 (1): 336-10.1186/1471-2407-12-336.CrossRefPubMedPubMedCentral
36.
Fredlund E, Staaf J, Rantala JK, Kallioniemi O, Borg A, Ringner M: The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition. Breast Cancer Res. 2012, 14 (4): R113-10.1186/bcr3236.CrossRefPubMedPubMedCentral
37.
Kawashima A, Takayama H, Kawamura N, Doi N, Sato M, Hatano K, Nagahara A, Uemura M, Nakai Y, Nishimura K: Co-expression of ERCC1 and Snail is a prognostic but not predictive factor of cisplatin-based neoadjuvant chemotherapy for bladder cancer. Oncology letters. 2012, 4 (1): 15-21.PubMedPubMedCentral
38.
Moreno-Bueno G, Portillo F, Cano A: Transcriptional regulation of cell polarity in EMT and cancer. Oncogene. 2008, 27 (55): 6958-6969. 10.1038/onc.2008.346.CrossRefPubMed
39.
Brabletz T, Jung A, Hermann K, Gunther K, Hohenberger W, Kirchner T: Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol Res Pract. 1998, 194 (10): 701-704. 10.1016/S0344-0338(98)80129-5.CrossRefPubMed
40.
Katoh M: Cross-talk of WNT and FGF signaling pathways at GSK3beta to regulate beta-catenin and SNAIL signaling cascades. Cancer Biol Ther. 2006, 5 (9): 1059-1064. 10.4161/cbt.5.9.3151.CrossRefPubMed
41.
Hipp S, Walch A, Schuster T, Losko S, Laux H, Bolton T, Hofler H, Becker KF: Activation of epidermal growth factor receptor results in snail protein but not mRNA overexpression in endometrial cancer. J Cell Mol Med. 2009, 13 (9B): 3858-3867. 10.1111/j.1582-4934.2008.00526.x.CrossRefPubMed
42.
Hipp S, Berg D, Ergin B, Schuster T, Hapfelmeier A, Walch A, Avril S, Schmalfeldt B, Hofler H, Becker KF: Interaction of Snail and p38 mitogen-activated protein kinase results in shorter overall survival of ovarian cancer patients. Virchows Arch. 2010, 457 (6): 705-713. 10.1007/s00428-010-0986-5.CrossRefPubMed
Metadata
Title
Snail1 expression in colorectal cancer and its correlation with clinical and pathological parameters
Authors
Feride Kroepil
Georg Fluegen
Daniel Vallböhmer
Stephan E Baldus
Levent Dizdar
Andreas M Raffel
Dieter Hafner
Nikolas H Stoecklein
Wolfram T Knoefel
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-145

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group

Research article

Cytostasis and morphological changes induced by mifepristone in human metastatic cancer cells involve cytoskeletal filamentous actin reorganization and impairment of cell adhesion dynamics

Technical advance

Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2V617F mutant allele detection

Research article

Higher rate of skin rash in a phase II trial with weekly nanoparticle albumin-bound paclitaxel and cisplatin combination in Chinese breast cancer patients

Research article

Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR

Research article

Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits